FBR 002
Alternative Names: FABENCOV; FBR-002Latest Information Update: 01 Sep 2023
At a glance
- Originator Fab entech
- Class Antivirals; Immunoglobulin fragments; Polyclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 19 Aug 2023 Fab entech terminates a phase IIb trial in COVID-2019 infections in Greece (IV) (EudraCT2022-002724-12)
- 28 Jul 2023 700348630 - CTP Push (NCT05279352/EudraCT2021-002390-25): Incorporated QC feedback
- 28 Jul 2023 Fab entech completes a phase II trial in COVID-2019 infections (In adults, In the elderly) in Greece (IV) (EudraCT2021-002390-25) (NCT05279352)